Chapter 26: Antipsychotic Agents and Their Use in Schizophrenia

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

So imagine you're standing in front of like a massive, incredibly complex audio mixing board.

Oh, like the ones in a recording studio, right?

With all the knobs and dials?

Yeah, exactly.

The kind with hundreds of sliding knobs and blinking lights everywhere.

And when we talk about a neurotypical brain, those sliders are perfectly balanced.

The music of reality just sounds clear and harmonious.

Right, everything is properly tuned.

But with schizophrenia, it's as if someone walked right up to that mixing board and just forcefully shoved specific volume sliders all the way up to the maximum.

Which is such a great way to visualize what we call the positive symptoms.

Exactly, the positive symptoms.

A patient is experiencing hallucinations, profound delusions, paranoia, severe agitation.

Basically, the sheer volume of reality just becomes deafeningly loud.

Yeah, and to take that mixing board analogy a step further, there are entirely different channels on that board that have been completely muted.

Oh, right.

And those are the negative symptoms.

Like the social withdrawal and the emotional blunting, right?

Exactly, the lack of motivation, poverty of speech.

Basically, the normal signal for human interaction is just gone, muted.

Wow.

And then there's a third piece to this, isn't there?

There is, yeah.

We also have to account for the cognitive symptoms.

You can sort of think of those as, well, like the physical wiring underneath that mixing board getting completely crossed.

Meaning what exactly for the patient?

It manifests as disordered thinking and inability to focus and really profound learning and memory difficulties.

And what's really interesting is that these subtle cognitive changes are often the canary in the coal mine.

Oh, meaning they show up first.

Exactly.

They can appear years before a patient ever experiences those loud, florid, positive symptoms like hallucinations.

That makes total sense.

So for everyone listening, today we're stepping into a really supportive one -on -one tutoring session tailored specifically for you, the advanced practice nursing and physician assistant student.

We know you've got exams coming up and this stuff is complex.

Totally.

Our mission for this deep dive is to master the pharmacotherapeutics of antipsychotic agents and their use in schizophrenia.

We are not just gonna like blindly memorize drug lists today.

No, that never works anyway.

Right.

We're gonna bridge the gap between the underlying pathophysiology and the actual clinical decisions you'll make for your patients.

Which is so critical.

Establishing that baseline really matters because frankly it's kind of difficult for modern practitioners to grasp just how revolutionary these medications actually are.

Oh, for sure.

I mean, before the first antipsychotics were introduced in the 1950s, getting a diagnosis of a severe psychotic illness was essentially a life sentence.

Patients were just locked away in institutions.

Yeah, completely.

Because medical science had absolutely no effective treatments to offer them back then.

It's a really stark reminder of why this pharmacology matters for you.

Today, because we can literally manipulate neurotransmitters, many of these patients can leave psychiatric hospitals, go back to their communities, and maintain independent lives.

It's life changing.

It really is.

But to understand how we do that, we have to look at the etiology first.

And while the exact root cause of schizophrenia remains, well, somewhat elusive,

the biologic foundation is pretty clear.

Right.

We know it's happening at the receptor level.

Exactly.

The primary culprits are an excessive activation of dopamine receptors in the central nervous system, coupled with an insufficient activation of glutamate receptors.

And that dopamine excess is the specific target for our oldest class of medications, which are the first generation antipsychotics, or FGAs.

You'll also see those referred to as conventional antipsychotics, or neuroleptics in practice, right?

Yeah, interchangeably.

And regardless of what you call them, every single FDA shares the exact same primary mechanism of action.

Okay, let's unpack that.

What's the mechanism?

They produce a profound blockade of dopamine two receptors, specifically the D2 receptors in the mesolimbic area of the brain.

And that area is heavily involved in emotion and reward.

Okay, so here is a crucial clinical pearl for everyone listening, that frequently trips up students on board exams.

Every single FGA is equally effective at relieving the symptoms of psychosis.

That's a huge point to remember.

Right, whether you prescribe a low potency prototype like chlorpromazine, or a high potency prototype like haloperidol, they both have the exact same ceiling of therapeutic benefit.

Which naturally brings up the concept of potency, right?

Because in pharmacology potency is, it's frequently misunderstood.

People think it means maximum effect or the strength of the drug.

But potency strictly refers to the size of the dose required to elicit a response.

I totally used to fall into that trap.

I just assumed a high potency drug like haloperidol was somehow like hitting the brain harder, curing the psychosis better.

A lot of people think that.

But it just means you need a much smaller milligram dose of haloperidol to achieve the exact same antipsychotic effect as say a massive dose of chlorpromazine.

Exactly, that is the core distinction.

And we categorize them by potency because the size of the dose correlates directly with drastically different side effect profiles.

So it's basically about picking your poison.

Essentially, yeah.

The choice between a high potency and low potency FGA is really a choice of which adverse effects your patient can best tolerate.

Wow, and the most significant consequence of these drugs stems directly from their mechanism of action, doesn't it?

It does.

Let's look at the physiology there.

Right, if the D2 blockade fixes the psychosis by turning down that dopamine volume slider in the emotion centers, we can't just isolate that blockade, right?

Well, the drug goes everywhere.

So it also blocks dopamine in the extra -preliminal motor system.

But wait, isn't a profound lack of dopamine in the motor system exactly what causes the tremors and rigidity in Parkinson's disease?

Yes, it is the exact same physiological state.

Oh, wow.

By inadvertently blocking dopamine in the brain's movement center, FGAs induce a whole spectrum of movement disorders that we collectively call extra -pyramidal symptoms or EPS.

And the timeline of when these EPS symptoms appear is absolutely critical for your clinical exams, isn't it?

Oh, absolutely.

And for your daily practice, the timeline dictates your intervention.

Okay, so let's walk through that timeline.

What happens first?

Well, within the first few hours to days of starting a patient on an FGA, they might develop acute dystonia.

And this is terrifying for a patient, right?

Completely terrifying.

We are talking about severe involuntary muscle spasms of the tongue, the face, the neck, or the back.

Like really intense spasms.

It's a true medical emergency.

The muscle contractions can be so forceful they actually cause joint dislocation.

Oh, my God.

Yeah, and if the spasm hits the larynx, you get laryngeal dystonia, which completely obstructs the airway.

So to treat acute dystonia, you obviously don't just wait it out.

You have to intervene rapidly with intravenous or intramuscular anti -cholinergic medication.

Right, things like benztropine or defenhydramine.

And by blocking acetylcholine, you basically rebalance the motor system and the symptoms typically resolve within what?

Five to 20 minutes.

Exactly.

Now, moving down the timeline,

within the first five to 30 days of therapy, a patient might develop Parkinsonism.

Okay, because we've blocked their dopamine.

Right, so they present exactly like someone with idiopathic Parkinson's disease.

You'll observe bradykinesia, a mask -like facial expression, drooling, tremors,

and that shuffling, rigid gait.

Okay, so imagine you're the prescriber listening to this.

Your patient suddenly looks like they have Parkinson's, which we know is caused by a lack of dopamine.

The logical thought is to simply prescribe levodopa, which is a dopamine precursor, to replenish what's missing.

Can we do that?

No, and that is the exact trap you must avoid on your exams.

Tell them why.

If you prescribe levodopa, it will convert to dopamine and activate those exact D2 receptors we just intentionally blocked.

Oh, so you'd directly counteract your antipsychotic medication.

Exactly, you would throw the patient right back into severe psychosis.

It's like a total pharmacological tug of war.

Precisely, so instead of adding dopamine, we treat FGA -induced Parkinsonism with centrally acting anticholinergics or a drug like amantadienic.

And it's also really important to educate the patient that this side effect is often transient.

The Parkinsonism frequently resolves spontaneously over a few months.

Meaning you could eventually taper them off the anticholinergic.

Exactly.

Now, between five and 60 days, a patient might experience akathisia.

And this is a one that's often misdiagnosed by new clinicians, right?

Yeah, because it looks like worsening psychotic agitation.

But it's actually a profound compulsive internal restlessness.

Like they just can't stop moving.

Right, the patient feels this unbearable urge to be in constant motion.

They're pacing the hall, squirming in their chair, just feeling incredibly anxious.

So when you identify akathisia, the first step is to just reduce the dosage of the antipsychotic if you can, right?

Yes, but if you can't reduce the dose without risking a psychotic relapse, you can manage that restlessness with beta blockers, benzodiazepines, or anticholinergics.

Okay, so those first three, acute dystonia, Parkinsonism, and akathisia, those are the early reactions.

But after months or even years of FGA therapy, patients are at risk for the late reaction, which is tardive dyskinesia, or TD.

And this is arguably the most troubling one.

Because for many patients, it's irreversible, isn't it?

Unfortunately, yes.

Tardive dyskinesia is characterized by involuntary choriofatoid movements.

What does that look like in practice?

You'll see twisting, writhing, worm -like movements of the tongue and face.

It often starts with really subtle lip smacking or fly -catching tongue movements.

And then it spreads.

Yeah, eventually it spreads to the limbs and trunk.

Historically, we had literally nothing to offer these patients.

But there is an incredibly exciting pharmacological update that you all need to know.

Yes, this is huge.

We now have FDA -approved treatments specifically for tardive dyskinesia.

They're called VMAT2 inhibitors, namely valbenazine and dutrabenazine.

The mechanism of these VMAT2 inhibitors is just fascinating.

Normally, the VMAT2 transporter acts kind of like a recycling truck.

Okay, how so?

It packages free dopamine back into the presynaptic vesicles so it can be used again.

Oh, I see.

So by inhibiting that transporter, these drugs leave the free dopamine out in the open nerve terminal where it gets rapidly degraded by enzymes.

So basically, by preventing the recycling, you deplete the overall amount of dopamine available to stimulate those supersensitive motor receptors that are causing all the writhing movement.

Exactly, it's a brilliant workaround.

It really is.

But as a prescriber, you do have to monitor the patient for adverse effects, right?

Yeah.

Like QT, interval prolongation, and heavy somnolence.

Definitely.

Now, you are much more likely to see these early EPS reactions with high -potency drugs like heloperidol.

But that doesn't mean the low -potency drugs like chlorpromazine are harmless.

Not at all.

Low -potency FGAs cause far fewer early movement disorders, sure, but they cause drastically higher rates of other issues.

Because they block multiple other receptor types in the body.

Let's break down that collateral damage.

Let's do it.

When low -potency FGAs block histamine receptors, the patient experiences heavy, debilitating sedation.

When they block alpha -adrenergic receptors, the blood vessels cannot constrict when the patient stands up, causing severe orthostatic hypotension and fainting.

And then when they block muscarinic receptors, you see intense anticholinergic effects.

Like bone -dry mouth, blurred vision, photophobia, and urinary retention.

We also have to monitor the neuroendocrine system closely,

because dopamine normally exerts an inhibitory effect on prolactin.

Okay, so when your FGA blocks that dopamine.

Prolactin levels just soar, and this can cause gynecomastia, which is breast growth, and galacteria, which is lactation.

In both male and female patients?

Yes, in both.

Wow.

And beyond the receptor blockades, there's a rare but really catastrophic reaction called neuroleptic malignant syndrome, or NMS.

And NMS carries up to a 20 % mortality rate if it goes unrecognized.

That's terrifying.

What are the physiological signs?

They're unmistakable.

You get lead pipe muscle rigidity, a sudden and soaring high fever, and total autonomic instability.

Meaning their heart rate and blood pressure are wildly fluctuating?

Exactly.

The dopamine blockade in the hypothalamus basically destroys the body's temperature regulation, causing that sudden fever.

And the severe striatal blockade causes the lead pipe rigidity.

Right, so if you suspect NMS, you immediately withdraw the anti -psychotic.

Treatment is heavily supportive, but you will often utilize dantrolene.

Which acts directly on the skeletal muscle to relieve the rigidity.

Or promypexel, which is a dopamine receptor agonist used to counteract the central nervous system toxicity.

Okay, before we move on from the classical drugs, there is a crucial safety alert you must commit to memory for your exams.

There is a black box warning that applies to all anti -psychotics regarding older adults with dementia -related psychosis.

This is paramount, especially if you're working in geriatrics or long -term care.

Using any anti -psychotic off -label to treat behavioral agitation or psychosis in older adults with dementia roughly doubles their mortality risk.

Doubles it, wow.

What are the fatalities primarily driven by?

Mostly heart failure and aspiration pneumonia.

The combination of sedation, altered swallowing mechanics, and cardiovascular strain is just simply too dangerous for this frail population.

Okay, so let's move our timeline forward a bit to the 1990s.

Pharmacology realized that the movement disorders caused by FGAs were just unacceptable for long -term quality of life.

Right, they were debilitating.

Thus, the second generation anti -psychotics, the SGA's or atypical anti -psychotics, were born.

But did we actually solve the problem or did we just trade devastating movement disorders for a completely different set of disasters?

Well, for a long time, the medical community assumed SGA's were the silver bullet.

The market shifted drastically because we thought they were inherently safer and more effective.

But that wasn't the whole story.

No,

massive government -sponsored trials revealed that, with one specific exception, SGA's and FGA's are basically equally effective at treating schizophrenia.

So the true paradigm shift was in their mechanism of action, which changed the adverse effect profile.

Exactly.

Drugs like olanzapine and quesapine still block dopamine, but they only exert a moderate blockade of D2 receptors.

Alongside a very strong blockade of serotonin, specifically the 5 -HT2 receptor.

Right, and because that D2 blockade is only moderate, the risk of developing extrapyramidal symptoms is dramatically lower.

But that lower EPS risk comes with a severe metabolic cost.

SGA's carry a massive risk of weight gain, nuance at diabetes,

and dyslipidemia.

The weight gain is pretty intense.

It's primarily driven by the blockade of H1 histamine receptors in the brain, which not only stimulates appetite, but also decreases basal body temperature and overall energy expenditure.

And these metabolic shifts are not merely cosmetic concerns for your patients.

They drastically increase the patient's risk for cardiovascular events and premature death.

Absolutely.

As a clinician, this completely changes your daily workflow.

You cannot just write a prescription for an SGA and send the patient on their way.

Your monitoring parameters have to be ironclad.

Yes.

You need an accurate baseline weight and then constant tracking.

You must draw a fasting blood glucose or an A1C at baseline at least every six months to catch nuance at diabetes.

And you must order a fasting lipid panel every six months too.

Right.

Because these drugs will actively raise total cholesterol, spike triglycerides, and totally tank the protective HDL cholesterol.

Which brings us to the prototype for the atypical class.

It's a drug of extremes,

clozapine.

Clozapine is fascinating because it breaks the rule we mentioned earlier about equal efficacy.

Right.

It is undeniably the most effective drug we possess for treatment -resistant schizophrenia.

When a patient has failed multiple other trials and the psychosis is unyielding, clozapine often works.

But the safety requirements are so intense, they literally feel like a full -time job for the prescriber.

They really do.

Clozapine carries a black box warning for severe neutropenia, historically referred to as a granulocytosis.

It occurs in roughly one to 2 % of patients.

And because neutrophils are the body's primary defense against bacterial invaders, depleting them leaves the patient entirely vulnerable to fatal gram -negative septicemia.

Exactly.

So to mitigate this risk, prescribers, pharmacies, and patients must enroll in the incredibly strict clozapine ORMS program.

Let's talk about the reality of this program because it is daunting.

Before you can even distance the first pill, the patient's white blood cell count must be greater than or equal to 3 ,500.

Right, and their absolute neutrophil count, the ANC, must be greater than or equal to 2 ,000.

And that initial blood draw is just the beginning, isn't it?

Oh yeah.

You are mandated to monitor their WBC and ANC weekly for the first six months.

Every single week.

Every week.

If they remain stable, you step down to every two weeks for the next six months.

And even after a year of stability, you still must draw blood every four weeks for the entire duration they are on the medication.

Wow.

And if that ANC ever drops below 1 ,000, you are required to stop treatment immediately.

Instantly.

And there is a second black box warning for clozapine that you have to watch out for, which is myocarditis.

A severe inflammation of the heart muscle.

Right.

If your patient on clozapine suddenly develops unexplained fatigue, chest pain, or difficulty breathing, you must withhold the drug instantly to rule out cardiac involvement.

Because if myocarditis is confirmed, that patient can never take clozapine again.

Never.

Furthermore, the drug interactions require immense vigilance.

You cannot co -administer clozapine with any other bone marrow -suppressing drugs.

And because it's heavily metabolized by the cytochrome P450 system in the liver,

introducing an inducer like phenytoin will accelerate its metabolism.

Causing the clozapine levels to drop way below the therapeutics threshold.

Conversely, introducing an inhibitor like erythromycin will halt its metabolism, rapidly raising clozapine to toxic levels.

You have to be so careful.

Okay, so we've covered the physiology and the risks, but let's talk about the clinical reality of administration.

It is one thing to write the perfect prescription.

Sure.

It's another thing entirely to ensure a patient experiencing profound paranoia and delusions actually swallows the medication.

Non -adherence is basically the greatest barrier to treating schizophrenia.

When a patient lacks insight into their illness, or when the metabolic and sedative side effects just become intolerable, they stop taking the medication.

So the pharmacology industry has had to develop highly creative delivery systems to ensure adherence.

They really have.

We have oral liquid concentrates, which are harder for a patient to hide in their mouth.

Though you must educate staff to avoid skin contact with those because they cause contact dermatitis.

Good point.

We also have a sublingual version of a centipede.

Because it dissolves instantly through the oral mucosa and enters the bloodstream directly, it physically prevents a patient from cheeking the pill and spitting it out later when the nurse turns around.

That's incredibly smart.

And for acute agitation in the emergency setting, there's inhaled loxapine, which enters the systemic circulation through the lungs for a very rapid onset.

There are transdermal patches too.

And then there is a remarkable innovation called Abilify MyYCIT.

Okay, this one sounds like actual science fiction.

Abilify MyYCIT is an oral erypiprazole tablet with a microscopic ingestible sensor built right into the pill.

Right into it, yeah.

When the patient swallows it and the sensor hits the stomach acid, it generates a tiny electrical signal.

A wearable patch on the patient's abdomen picks up that signal and transmits a timestamp to a smartphone app, verifying the pill was actually digested.

It raises fascinating clinical implications, doesn't it?

On the surface, giving a pill with a tracking microchip to a patient suffering from paranoid delusions seems entirely counterintuitive.

Yeah, like playing right into the delusion.

However, the objective data it provides is invaluable.

Without that data, a clinician might see a relapsing patient and incorrectly assume the drug isn't working.

Prompting them to unnecessarily increase the dose or switch medications.

Right, when the reality is simply that the patient wasn't swallowing the pill.

Makes sense.

But the most reliable tool we have for long -term adherence is the depo preparation.

And we really need to dispel the pervasive myth here for the student.

Yes, please.

Many students and even practicing clinicians view long -acting intramuscular or subcutaneous depo injections, like haloperidol decanoid or risperdal consta as a punishment for bad or nonadherent patients.

And that stigma is entirely unfounded and medically incorrect.

Depo injections, which are administered every two to 12 weeks, depending on the specific formulation, are actually a first -line clinical tool for any patient requiring long -term therapy.

Let's look at the pharmacokinetics of why they are superior.

When a patient takes a daily oral pill, their blood levels look like a jagged mountain range.

Sharp peaks and deep valleys.

Right, sharp peaks of toxicity shortly after swallowing, followed by deep troughs where the drug wears off and symptoms begin to return.

Depo preparations eliminate those peaks and troughs completely.

They provide a slow, steady, continuous absorption into the bloodstream.

And because you avoid those toxic peak concentrations, the total overall drug burden on the patient's body over time is actually lower than with daily oral dosing.

Which is counterintuitive for a lot of people.

Because the total drug burden is lower, the risk of developing tardive dyskinesia is actually reduced with depo injections, not increased.

Oh, wow.

And because the drug never drops into a trough, the rate of psychotic relapse just plummets.

So bringing all of this pharmacology back to your daily practice,

how do you actually choose a drug?

The prescribing algorithm for schizophrenia rests on three foundational pillars.

Efficacy, tolerability, and cost.

And since we've established that FGAs and SGA's are generally equally effective, barring clozapine for treatment -resistant cases, the first pillar is essentially a tie.

That means your decision almost entirely hinges on tolerability, which requires looking at the specific patient sitting right in front of you.

Exactly.

If you are evaluating a patient with a strong family history of diabetes, or someone who is already severely obese, an SGA like olanzapine is highly contraindicated due to the metabolic risks.

So you would steer towards a metabolically neutral SGA like aripiprazole, or maybe lean towards a high -potency FGA instead.

Right.

And if all clinical factors and side effect risks are relatively equal, you look at cost.

FGAs are older, available as generics, and vastly cheaper for the patient and the healthcare system than the newer SGA's.

Once you make that choice, patient education is your next priority.

You must set realistic expectations regarding the timeline of therapeutic effect.

Right, because it's not instant.

A patient might see agitation begin to resolve in one to two days, but the true, full anti -psychotic effect takes months to fully manifest.

Initially, doses are divided throughout the day to build tolerance.

But once the patient is stable, a great clinical hack is to consolidate the entire dose to bedtime.

Yes, I love this strategy.

Since almost all of these drugs cause sedation, giving it at night utilizes that side effect to help the patient sleep.

While minimizing their daytime drowsiness.

Exactly.

You also must educate the patient and their family that while anti -psychotics are not drugs of abuse, they cannot be abruptly discontinued.

Oh, definitely not.

Sudden withdrawal will precipitate a severe cholinergic rebound, right?

Yes.

Featuring insomnia, profound restlessness, and diaphoresis, they must be slowly tapered.

This is incredibly critical for your pregnant patients too.

Neonates exposed to anti -psychotics in the third trimester can suffer from both withdrawal symptoms and extra -pyramidal movement disorders upon birth.

Medication management during pregnancy is just a very delicate balance of maternal sanity versus fetal risk.

Ultimately, you must remember that pharmacology is only one piece of the puzzle.

Drugs alone do not constitute comprehensive treatment.

No, these patients require holistic care.

Behavioral therapy to manage stress, family counseling, and vocational training to build a life in the community.

It is really profound to reflect on the fact that by simply manipulating microscopic neurotransmitters like dopamine and serotonin, we can literally change the fabric of a person's reality.

This is amazing.

We have transformed schizophrenia from an automatic institutional life sentence into a manageable chronic illness.

But our current tools are still incredibly blunt.

They are.

We are constantly forcing patients to trade their sanity for severe physical tolls, whether that's the irreversible movements of tardide dyskinesia or the life -shortening impacts of metabolic syndrome.

It leaves us with an important question for the future of your careers.

If manipulating dopamine and serotonin comes with such a heavy physiological tax, what is the next frontier?

That's a great question.

As we noted at the very beginning, glutamate pathways are heavily implicated in the etiology of schizophrenia.

Developing targeted therapies that modulate glutamate without wrecking the motor in metabolic systems could represent the next great pharmacological revolution.

And that is exactly why understanding the why behind the guidelines is everything.

You aren't just memorizing tables for a test.

You're learning how to keep the sliders on that mixing board balance so your patients can hear the music of their lives clearly.

Beautifully said.

To all the advanced practice nursing and PA students studying for your exams out there, thank you for joining us.

From everyone on the last minute lecture team, we wish you the absolute best of luck on your clinical journey.

Keep diving deep.